Personalized Therapies for Atrial Fibrillation. A Translational Approach.
Training programme exploring the potential of personalized medicine in atrial fibrillation.
Human R&D, Training
H2020-MSCA-ITN-2019 – Grant Agreement ID 860974
1 February 2020 to 31 January 2024
Atrial Fibrillation (AF) is the most common cardiac arrhythmia affecting more than 6 million Europeans. New treatment strategies and the progress achieved in research on AF mechanisms and substrate evaluation methods to date have not been proportionate with an equivalent development of the knowledge and technologies required to individually characterize each patient in search of the most efficient therapy. PersonalizeAF addresses this challenge by delivering an innovative multinational, multi-sectorial, and multidisciplinary research and training program in new technologies and novel strategies for individualized characterization of AF substrate to and increase treatments’ efficiency. PersonalizeAF will integrate data and knowledge from in vitro, in silico, ex vivo and in vivo animal and human models to: 1) generate an individual description of the state of the atrial muscle identifying the disease mechanisms and characteristics; 2) understand the potential effect that different therapies have on different atrial substrates; and 3) combine this information to generate a specific profile of the patient and the best therapy for each patient.. Within this framework, GenomeScan hosts secondments and provides its expertise in Next Generation Sequencing (NGS) in order to identify the main genetic and transcriptomic biomarkers for AF progression.
T.b.a. (ongoing project)
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860974.